Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Journal of the American Academy of Dermatology|April 14, 2018
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasisClaus Zachariae, Kenneth Gordon, Alexandra B Kimball, et al.Advances in Therapy|September 22, 2023
The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records DatabasesDarmendra Ramcharran, Bruce Strober, Kenneth Gordon, et al.Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.Journal of the American Academy of Dermatology|March 4, 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball, Dafna Gladman, Joel M Gelfand, et al.Journal of Drugs in Dermatology : JDD|March 4, 2011
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indicationsAlice B Gottlieb, Kenneth Gordon, Edward H Giannini, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 2, 2017
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque PsoriasisHema N Viswanathan, Alex Mutebi, Cassandra E Milmont, et al.JAMA Dermatology|December 20, 2023
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical TrialKim A Papp, Kenneth Gordon, Bruce Strober, et al.The Journal of Dermatological Treatment|December 20, 2012
Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severityMona L Martin, Kelly P McCarrier, Chiun-Fang Chiou, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 28, 2019
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasisRichard G B Langley, Kristian Reich, Vibeke Strand, et al.The Journal of Clinical Investigation|July 1, 2025
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flaresJames G Krueger, Mrinal K Sarkar, Mark G Lebwohl, et al.Pageof 4